# Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

> **NCT02926950** · PHASE3 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 518 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sotagliflozin (SAR439954)
- **DRUG:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02926950
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-02-26
- **Final completion:** 2019-03-22
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926950, "Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02926950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*